EJCTS Click here to go to Edwards website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Eur J Cardiothorac Surg 2008;33:829-836. doi:10.1016/j.ejcts.2008.01.063
Copyright © 2008, European Association for Cardio-thoracic Surgery. Published by Elsevier. All rights reserved.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Nicola Santelmo
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pourel, N.
Right arrow Articles by Reboul, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pourel, N.
Right arrow Articles by Reboul, F.
Related Collections
Right arrow Lung - cancer

Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response

Nicolas Pourela,*, Nicola Santelmoc, Nidal Naafac, Antoine Serrea, Werner Hilgersb, Laurent Mineura, Nicolas Molinarid, François Reboula

a Radiation Oncology Department, Institut Sainte-Catherine, France
b Medical Oncology Department, Institut Sainte-Catherine, France
c Thoracic Surgery Department, Centre Hospitalier Henri Duffaut, Avignon, France
d Laboratoire de Biostatistique, Faculté de Médecine, Université de Montpellier, service DIM, CHU de Nîmes, France

Received 20 July 2007; received in revised form 17 December 2007; accepted 16 January 2008.

* Corresponding author. Address: Radiation Oncology Department, Institut Sainte-Catherine, 1750, chemin du Lavarin, BP 846, 84082 Avignon Cedex 2, France. Tel.: +33 49 0276031; fax: +33 49 0276029. (Email: n.pourel{at}isc84.org).


   Abstract
Top
 Abstract
1. Introduction
 2. Patients and methods
 3. Results
 4. Discussion
 5. Conclusion
 Appendix A
 References
 
Introduction: Optimal preoperative treatment of stage IIB (Pancoast)/III non-small cell lung cancer (NSCLC) remains undetermined and a subject of controversy. The goal of our study is to confirm feasibility and pathological response rates after induction chemoradiation (CRT) in our community-based treatment center. Patients and methods: Patients were selected according to functional and resectability criteria. Induction treatment comprised 3D conformal 4500 cGy radiotherapy delivered to the primary tumor and pathologic hilar and/or mediastinal lymph nodes on CT scan with an extra-margin of 1–1.5 cm. Concurrent chemotherapy regimen was cisplatinum 20 mg/m2 d1–d5 and etoposide 50 mg/m2 d1–d5, d1–5 d29–33. Within 3–4 weeks after CRT completion, operability was re-assessed accordingly. Surgery was performed 4–6 weeks after CRT completion in patients (pts) deemed resectable. Inoperable pts were referred for a 20–25 Gy boost ±1 extra-cycle of cisplatinum + etoposide. Results: From 1996 to 2005, 107 pts were initially selected for treatment and received induction chemoradiation (stage IIB-Pancoast 18, IIIA 58 and IIIB 31, squamous cell carcinoma 48%, adenocarcinoma 44%, large-cell undifferentiated carcinoma 14%). After preoperative evaluation, 72 pts (67%) had a thoracotomy (pneumonectomy 21, lobectomy 45, bilobectomy 5) and all but one (unresectable tumor) had a macroscopic complete resection. During the 3-month postoperative time, five patients (6.9%) died, four after pneumonectomy (right 3, left 1). The analysis of tumoral samples showed a pathological complete response rate or microscopic residual foci of 39.5%. Median follow-up time was 22.3 months (survivors: 36.8 months), 2-year and 3-year overall survival rates were 55% and 40%, respectively (median = 26.7 months) for all the intention-to-treat population (n = 107), 62% and 51% (median = 36.5 months) for 71 resected pts, 41% and 16% for 36 non-resected pts (median = 19.1 months). On multivariate analysis, surgical resection and tumoral necrosis >50% (or pathological complete response) were the most pertinent predictive factors of the risk of death (hazard ratio = 0.50 and 0.48, p = 0.006 and 0.038, respectively). Conclusion: Surgery was feasible after induction chemoradiation, particularly lobectomy in PS 0–1, stage IIB (Pancoast)/III NSCLC pts but pneumonectomy carries a high risk of postoperative death (particularly, right pneumonectomy). Pathological response to induction chemoradiation was complete in 39.5% of patients and was a significant predictive factor of overall survival.

Key Words: Induction • Chemoradiation • Surgery • Non-small cell lung cancer • Combined modality treatment


   1. Introduction
Top
 Abstract
 1. Introduction
2. Patients and methods
 3. Results
 4. Discussion
 5. Conclusion
 Appendix A
 References
 
Optimal treatment strategy of patients (pts) presenting with stage IIIA/B and superior sulcus T3N0-Pancoast (stage IIB) non-small cell lung cancer (NSCLC) has yet to be determined. Surgery alone generally results in a poor outcome with median overall survival time (MST) of 10–15 months and few long-term survivors (less than 10%) [1–3]. Several phase III studies have shown conflicting results concerning the role of induction chemotherapy (CT) + surgery versus surgery alone (±postop. RT) with a significant increase in MST in Roth et al. [3] (64 months vs 11 months, p = 0.008), Rosell et al. [2] (26 months vs 8 months, p < 0.001) and Pass et al. [1] studies (28.7 months vs 15.6 months, p = 0.095) while Depierre et al. [4] observed a less important difference (25.0 months vs 18.9 months, p = 0.15). A more recent phase II study by Betticher et al. [5] using a 3rd generation CT regimen (cisplatinum and docetaxel) has shown promising results after induction CT with a median overall survival time of 33 months among 90 stage IIIA(N2) patients (median follow-up time: 32 months). In this study, mediastinal clearance and complete resection were strong predictors of survival on multivariate analysis.

Induction chemoradiation (CRT) is a promising therapeutic concept in locally advanced NSCLC, from stage IIB-Pancoast to stage IIIA(N2) and operable IIIB (mainly T4N0–1), whereas non-Pancoast stage IIB are accessible to upfront surgery. While CT alone yields pathological complete response (pCR) rates ranging from 3.7–19% [1–5], CRT achieves 21–65% pCR rates in three successive phase II SouthWest Oncology Group (SWOG) and Intergroup (INT) trials [6–8] among stage IIB (Pancoast) and IIIA patients. Pathological response to induction CRT was associated with MST ranging from 30 to 36.7 months [9]. In addition, CRT also does not result in excessive postoperative (postop.) mortality when combined with lobectomy (less than 6.3% within 30 days postop.).

The goal of our confirmatory study was to reproduce the results of the previous SWOG and INT studies, using a similar regimen of 2 cycles of cisplatinum + etoposide chemotherapy and 4500 cGy radiotherapy delivered with a homogenous 5-field 3D conformal technique in a community-based comprehensive cancer center and thoracic surgery unit (Institut Sainte-Catherine and Centre Hospitalier Henri Duffaut, Avignon, France) among stage IIB/III NSCLC patients. Our primary endpoint was pathological complete response rate. Secondary endpoints were postoperative morbidity/mortality and survival.


   2. Patients and methods
Top
 Abstract
 1. Introduction
 2. Patients and methods
3. Results
 4. Discussion
 5. Conclusion
 Appendix A
 References
 
2.1 Eligibility criteria
Patients with potentially operable, locally advanced NSCLC, stage IIB (T3N0 superior sulcus, Pancoast) or stage III (bulky N2 and N3 excluded) with performance status (PS) ranging from 0 to 2 and age from 18 to 80 were proposed CRT after multidisciplinary validation of treatment indication (thoracic surgeon, pneumologist, radiation oncologist and medical oncologist).

Pretreatment evaluation included a thoracic and upper abdomen computed tomography scan (CT scan), a brain magnetic resonance imaging (MRI) and a bone scan. Positron emission tomography scan (PET scan) was used later on when it became routinely available in 2004. Mediastinoscopy was performed in case of doubtful lymph node involvement in the mediastinum on CT scan (or PET scan when available).

Definitive staging was assessed during a multidisciplinary discussion about treatment indication and the initial CT scan was systematically peer reviewed. For Pancoast tumors, indication for CRT was based on marginal resectability as assessed by the surgeon.

Additional eligibility criteria to treatment were an adequate pulmonary function (predicted forced expiratory volume in 1 s (FEV1) >40% or in between 30 and 40% with an adequate VO2 max >15 ml/kg) and biological parameters (leukocytes >4000/mm3, platelets >100,000/mm3, creatinine clearance >60 ml/min). Cardiac function was assessed by ultrasound in case of a cardiac history.

2.2 Study design and follow-up
Patients were given a radiotherapy (RT) regimen comprising 4500 cGy in 180 cGy fractions (fr.), 5 fr./week over 5 weeks using a uniform conformal 5-field technique. Gross tumoral volume (GTV) was delineated from an iodine-injected helical CT scan. Planned target volume (PTV) was extrapolated from GTV using an automated isotropic 10–15 mm expansion. Field arrangement was optimized per patient to ensure a coverage of 100% of PTV by 95% of the prescribed dose (according to the International Commission on Radiation Units (ICRU) standards). Dose to spinal cord had to be maintained under 4500 cGy.

Concurrent CT consisted of two cycles of cisplatinum and etoposide: P 20 mg/m2/d1–d5 and d29–d33, E 50 mg/m2/d1–d5 and d29–d33 (PE).

Three to four weeks after CRT completion, patients were reassessed by physical examination, thoracic, upper abdominal CT scan and blood tests. PET scan and/or mediastinoscopy were not routinely performed at that particular time of treatment schedule. In the absence of disease progression (i.e. stable disease or partial/complete response), patients were referred for surgery. In the case of tumor progression, patients were referred for salvage treatment with hypofractionated radiotherapy (25–30 Gy/10 fractions/2 weeks with or without 1 extra PE cycle).

Surgery was performed 5–6 weeks after CRT completion: lobectomy, bilobectomy or pneumonectomy were allowed, accessible hilar and mediastinal lymph nodes were systematically removed, appropriately labeled and separately analyzed by the pathologist. Wedge-resection was not allowed. When a pneumonectomy was performed, a pleural flap was made on the bronchial stump.

In case of contra-indication to surgery, a radiotherapy boost consisting of 2000–2500 cGy/10–15 fr. with concurrent PE (1–2 cycles) was performed.

Postoperative chemotherapy and/or radiotherapy were also allowed according to the same modalities in case of R1/2 surgical resection or in case of pN2 disease.

Acute complications from CRT were compiled from individual patient records and rated according to the National Cancer Institute; Common Toxicity Criteria scale version 2.0 (NCI CTC v2.0). Surgery perioperative morbidity and mortality was prospectively collected and recorded in the EPITHOR database of the Société Française de Chirurgie Cardio-Vasculaire et Thoracique (SFCVT).

Follow-up comprised physical examination, blood tests and chest plain radiographs (abdominal ultrasound or thoracic) and upper abdominal CT scan every 3 months for the first 2 years, every 6 months from the 3rd to the 5th year and annually thereafter. Brain MRI was performed annually for the first 2 years.

2.3 Statistical analysis
Categorical variables were illustrated by frequency tables. Their influence on the probability of CRT complication, postoperative complication and death was assessed by the chi-square test. Actuarial overall and relapse-free survival of the intention-to-treat population was estimated by the Kaplan–Meier method and comparisons between groups were performed using the log rank test. The association between overall and relapse-free survival and a potential predictive or prognostic factor (clinical, pathological, staging, treatment) was investigated separately for each individual factor (univariate analysis). The predictive and prognostic impact of the variables was then investigated using the Cox multiple regression analysis: significant predictive factors in univariate analysis were introduced into a proportional hazard model and adjusted to potential confounding variables (gender, age, PS, stage). Hazard ratios illustrating the risk of death (HR) and corresponding 95% confidence intervals (CI95) are mentioned. All reported p values are two-sided.


   3. Results
Top
 Abstract
 1. Introduction
 2. Patients and methods
 3. Results
4. Discussion
 5. Conclusion
 Appendix A
 References
 
3.1 Patients
From 1996 to 2005, 107 patients received induction CRT. Patients’ characteristics are summarized in Table 1 . There were 91 males and 16 females with a median age of 59 (range: 31–81). Most of them (94%) were PS 0–1 at the onset of treatment, a small proportion presenting with a PS 2 (6%).


View this table:
[in this window]
[in a new window]

  		Table 1 Patients’ characteristics
 
Almost half of treated cancers were squamous cell carcinomas (48%), while others were either adenocarcinomas (38%) or undifferentiated large-cell carcinomas (13%); only one neuro-endocrine large-cell carcinoma was treated in our cohort (1%). The upper lobe was the most frequent tumor location (86 patients, 80%) followed by the lower lobe (17 patients, 16%); middle lobe and central tumors were infrequent (4 patients, 4%).

There were 18 patients with stage IIB (17%, all T3N0 Pancoast), 58 with stage IIIA (54%) and 31 stage IIIB tumors (29%). At initial evaluation, 66 patients (62%) were clinical N2 (cN2) with at least one significant adenopathy (i.e. short axis >1 cm) in the mediastinum on CT scan while 21 T4 patients were N0 and 20 T3 (Pancoast) patients were N0/N1.

3.2 Induction chemoradiation
Chemoradiation was discontinued in two patients: one sudden death due to an unrelated cause (rated as non-treatment related) occurred among the 107 patients who were proposed induction CRT and one patient refused treatment before CRT completion (RT dose delivered: 19.8 Gy + 1 cycle of PE).

Among the 105 remaining patients, 103 received two cycles of PE and 2 received only one: 1 patient with grade 3 fatigue and 1 patient with cisplatinum-induced renal failure. Regarding radiotherapy schedule, 102 patients received the planned 25 fractions of 180 cGy except three: two patients received only 24 fractions due to grade 3 fatigue, one patient received only 23 fractions due to an unrelated reason. Response to treatment was adequately assessed in 100 patients: there were 11 progression, 89 stable disease or partial/complete response.

Significant acute toxicity (grades 3–4, NCI-CTC v2.0 scale) due to induction CRT was infrequent in patients who completed treatment (n = 105): fatigue in three patients and renal failure in one patient were the cause of CT and/or RT discontinuation (Table 2 ). Febrile neutropenia, esophagitis and pneumonia were only transient events and did not interfere with treatment completion.


View this table:
[in this window]
[in a new window]

  		Table 2 CRT acute toxicity (NCI-CTC v2.0 scale, n = 105 pts a )
 
3.3 Surgery
Among the 105 patients who completed induction CRT, 72 patients had a thoracotomy (Fig. 1 ): there were 65 R0 resections, 4 R1 resections, 2 R2 resections, 1 exploratory thoracotomy only. The other 33 patients did not have any surgery (Fig. 1): 11 patients presented with tumor progression, 22 presented with a contraindication for surgery at the time of preoperative restaging and/or refused surgery (Table 3 ).


Figure 1
View larger version (13K):
[in this window]
[in a new window]

  		Fig. 1. Patterns of treatment.

 

View this table:
[in this window]
[in a new window]

  		Table 3 Surgery results (n = 105 pts)
 
For stage IIB, IIIA and IIIB patients, 72%, 72% and 57% (p = 0.488) were resected, respectively and there was only one unresectable stage IIIB (T4N2) tumor. Other categorical variables significantly influenced the probability of surgical resection such as age (median age: resected patients 58 years vs non-resected 66 years, p = 0.0084) and histology (proportion of resected patients: SCC 53%, adenocarcinoma 85%, large-cell carcinoma 71%, p = 0.00459). Gender, PS, tumor localization, clinical stage, year of treatment did not have a significant influence on the probability of being resected.

Type of surgery consisted in lobectomy in 45 patients (63%), bilobectomy in 5 patients (7%) and pneumonectomy in 21 patients (29%). Exploratory thoracotomy only was performed in one patient (1%).

3.4 Morbidity and mortality
Perioperative morbidity and mortality are detailed in Table 4 . There were five perioperative deaths among 72 patients who underwent surgery (3-month mortality, crude rate: 6%): two within the first 30 days (1st month mortality, crude rate: 3%), three within the 30–90 days postop. Two patients died of pulmonary embolism at day 5 and 52, two of sepsis (empyema and multi-organ failure) at day 27 and 53, one of pneumonia (amiodarone-induced) at day 43. In these five patients, four had undergone pneumonectomy (right 3, left 1) and one lobectomy (upper right).


View this table:
[in this window]
[in a new window]

  		Table 4 Perioperative morbidity/mortality within 3 months (pts with surgery: 72)
 
Significant perioperative morbidity occurred in 34 patients (Table 4): there were three complications in 5 patients, two in 6 patients and one in 23 patients. The most frequent events were arrhythmia (n = 10), pneumonia (n = 8), prolonged air leak (n = 7), fistula (n = 4), empyema (n = 4), atelectasis (n = 4) and hemorrhage (n = 4). Others were infrequent but some of them lethal (3 or less events: recurrent laryngeal nerve palsy, pulmonary embolism, septicemia, lymphorrhea, bronchorrhea).

Almost 43% of all patients encountered at least one postoperative complication whatever the surgical procedure (p = 0.76). Patients who underwent pneumonectomy had a higher number of complications than others with an average per patient of 1.82 against 1.3 but the difference was not statistically significant (p = 0.15) and a significantly higher risk of death (crude rates: 19% vs 2%, p = 0.039).

3.5 Boost chemo-radiotherapy
Among the 33 patients who were not surgically resected, 28 had a boost RT only, 3 had a boost CRT and 2 had no other treatment. Among the 72 surgically resected patients, 57 had no other treatment, 11 had a boost CRT (2 R2 resections, 4 R1 resection and 5 pN2R0), 4 had chemo only (2 pN1R0, 2 pN2R0). There were no severe complications related to boost RT and/or chemo.

3.6 Pathological response and mediastinal clearance
Pathological response rate to induction treatment was evaluable in 71 surgically resected patients (T any N any): a pathological complete response (or microscopic residual foci, i.e. necrosis >95%) was observed in 28 patients (39.5%), necrosis of tumoral tissues was over 50% but less than 95% in 16 patients (22.5%) and less than 50% in 27 patients (38%).

Mediastinal clearance was evaluable in 46 surgically resected patients with pathological lymph nodes at initial evaluation (T any cN2): 28 patients (61%) were pN0/N1 while 18 patients (39%) still had metastasis in the mediastinum (pN2).

3.7 Relapse and survival
The median follow-up time for the intention-to-treat population (n = 107) was 22.3 months and for the surviving patients 36.8 months. At the time of statistical evaluation of survival, 2 patients were lost to follow-up, 38 patients were alive (disease-free 32, with disease 6) and 67 patients had died (due to cancer 53, due to treatment complications 5, due to a second cancer 1, due to a non-cancer event 6, due to an unrelated event 2).

Actuarial overall survival rate (OS) was 55% at 2 years, 40% at 3 years and the med. OS time was 26.7 months For the patients who underwent surgery and were adequately resected (n = 71), OS was 62% at 2 years, 51% at 3 years and median OS time was 36.5 months. For the non-resected (n = 36), OS was 41% at 2 years, 16% at 3 years and med. OS time was 19.1 months (Fig. 2 ).


Figure 2
View larger version (18K):
[in this window]
[in a new window]

  		Fig. 2. (a) Overall survival (intention-to-treat population), n = 107 pts. (b) Overall survival (resected vs not resected pts), n = 107 pts.

 
Actuarial relapse-free survival rate (RFS) was 40% at 2 years, 35% at 3 years and the median RFS time was 15.2 months. For the patients who underwent surgery and were adequately resected (n = 71), RFS was 43% at 2 years, 41% at 3 years and med. RFS time was 20.9 months. For the non-resected patients (n = 36), RFS was 28% at 2 years, 23% at 3 years and median RFS time was 12.6 months.

At the time of evaluation, 56 patients had relapsed and 3 others were lost to follow-up. The most frequent site of relapse was distant only (37 patients, 66%) followed by local only and concurrently local + distant (10 and 9 patients, 18% and 16%, respectively).

Occurring as a first site of relapse, local failures were all located ‘in-field’, i.e. within the volume receiving full dose RT. Regarding distant failure, the most frequent sites of relapse were brain (n = 22) followed by lungs (n = 15) and adrenal glands (n = 6); relapse in the bones (n = 4), liver (n = 2), extra-thoracic nodes (n = 3), pleura (n = 1) and others (n = 3) was infrequent. In seven patients, two or more sites were involved simultaneously (two in four patients, three in three patients).

3.8 Prognostic factors
On univariate analysis, resected patients had a significantly better outcome in terms of OS: MST of patients who underwent surgery was 36.4 months while in others MST was 19.1 months (p = 0.002). Among resected patients (n = 71), there was a trend for better outcome in lobectomy patients versus pneumonectomy patients (MST: 50.5 months vs 23.1 months, p = 0.12). The pathological response to induction CRT had also a significant influence on OS: in patients who underwent surgery, those who had a tumoral necrosis of more than 50% (or residual microscopic foci or a pathological complete response) had a better outcome than patients with less than 50% necrosis (MST 48.7 months vs 22.3 months, p = 0.048). Mediastinal clearance had no significant influence on OS: pN2 patients had a MST of 21.9 months while pN0–1 had a MST of 29.9 months (p = 0.61). Stage (IIB vs IIIA/B) also had a borderline influence on the risk of death (p = 0.04) that was not confirmed on multivariate analysis. Other categorical variables such as age, gender, PS, histological sub-type had no significant influence on OS.

On multivariate analysis (Table 5 ), surgical resection remained a significant predictive factor of OS with a risk reduction of death of 56% compared to boost CRT without surgery (HR = 0.440, 95% CI = [0.252–0.747], p = 0.0026). The risk reduction of death associated with tumoral necrosis (Fig. 3 ) also remained significant (HR = 0.504, 95% CI = [0.263–0.960], p = 0.038). Conversely, stage lost significance with a HR of 1.39 (p = 0.36).


View this table:
[in this window]
[in a new window]

  		Table 5 Prognostic factors for overall survival
 

Figure 3
View larger version (14K):
[in this window]
[in a new window]

  		Fig. 3. Overall survival of resected pts dependant on pathological response, n = 71.

 

   4. Discussion
Top
 Abstract
 1. Introduction
 2. Patients and methods
 3. Results
 4. Discussion
5. Conclusion
 Appendix A
 References
 
The optimal treatment of stage IIB/III NSCLC remains a subject of controversy. Several treatment strategies have been tested without drawing definitive conclusions. In our institution, we have been using induction CRT since the 90s following the report of SWOG-8805 trial [6]. In 1996, the implementation of 3D-conformal RT brought a substantial improvement in terms of tolerance and coverage of the GTV. In our series, all patients had 3D-conformal RT combined to a systemic dose cisplatinum-etoposide chemotherapy regimen; prophylactic mediastinal irradiation was not allowed. In this setting, CRT was feasible with only one refusal, one sudden death (unrelated cause) and 22 severe acute complications (grades 3–4 febrile neutropenia n = 2, pneumonia n = 2, esophagitis n = 6, others n = 12, no grade 5).

Among 105 patients who received CRT, 2/3 were actually operated on (n = 71, 68%). This resection rate was actually lower than in other series [6,8,10–14]. Among the 34 patients who were not resected, primary resistance to CRT (n = 11, 10%) was the first cause that is comparable to previously published data [14]. Contra-indication for surgery (n = 23, 22%) was the other cause due to various reasons (refusal, poor general status, anatomical presentation of tumor after induction treatment) indicating that selection of patients referred for surgery was very careful in our multi-disciplinary practice.

Median survival of patients (n = 36) who were not deemed resectable after CRT reached 19 months which is comparable to results in many series of inoperable stage III NSCLC [8,15–18].

Postoperative mortality rate (0–3 months) was acceptable in patients who received lobectomy (or bilobectomy) and was as low as 2%. Therefore, in our opinion, candidates for such surgical procedures at the time of initial work-up should be referred for trimodality treatment. On the contrary, a pneumonectomy was associated with a high risk of postoperative mortality (19%) and should not, in our opinion, be performed after CRT in stage III disease without using specific procedures like the reinforcement of bronchial stump with a pedicled muscle [19,20]. These results are interestingly similar to those of the INT-0139 trial [8].

Our primary objective was pathological response to CRT: an impressive complete response (or microscopic residual foci) rate of 39.5% compares favorably to previously published data [5,6,8,10–14]. Similarly, multivariate analysis of overall survival consistently showed that necrosis of primary tumor and lymph nodes (50% or more, 62.5% of patients) was significantly associated with a better outcome (p = 0.048). These results might be due to the selection of patients and also the systematic use of conformal 3D radiotherapy. The role of mediastinal clearance could not be adequately assessed in our series because of the lack of systematic PET or mediastinoscopy before CRT was started. Therefore we assume that the absence of significant difference in the prognosis of pN0–1 versus pN2 patients might be due to the confounding effect of misclassification.

We are aware of the limitations of the preoperative staging during the period of time of our study (1996–2005) in terms of PET scan and mediastinoscopy. Therefore, survival results should be regarded with caution. Nevertheless, overall survival of resected patients was encouraging with a median of 37.5 months and a 3-year rate of 51%. These results are consistent with recently published data [Park, Kwong] based on 3-D conformal RT and seem to be superior to those observed after bimodality treatment like concurrent CRT alone [16–18] or induction chemotherapy followed by surgery [1–4]. Only a well designed randomized trial will answer to this question: in INT-0139, the surgery arm patients did not have a better outcome in terms of overall survival because of the excess mortality attributable to pneumonectomy. Stage III disease is indeed a very heterogeneous group of patients and ‘optimal’ selection of patients to be operated on might be the key to improvement of outcome. Surgery is a major prognostic factor in our series (vs no surgery) and we assume the concept that among stage III patients, some should receive surgery whenever feasible at initial work-up. Pneumonectomy (particularly, right-sided) should be regarded with caution and remains an option in selected patients when adequate procedures are available and feasible.

In the future, PET CT could become a surrogate for the selection of patients to be referred for surgery: Schmuecking et al. [21] have shown that metabolic response after induction CRT, evaluated within 1 week following its completion, is highly predictive of pathological response.


   5. Conclusion
Top
 Abstract
 1. Introduction
 2. Patients and methods
 3. Results
 4. Discussion
 5. Conclusion
Appendix A
 References
 
In our study, surgery was feasible after induction CRT, particularly lobectomy, in PS 0–1 stage IIB (Pancoast)/III NSCLC patients. Pathological response to induction CRT was high and a major predictive factor of OS (necrosis >50% or pCR). Survival of resected patients was encouraging. A randomized trial is needed to determine whether induction CRT is superior to induction CT alone.


   Appendix A
Top
 Abstract
 1. Introduction
 2. Patients and methods
 3. Results
 4. Discussion
 5. Conclusion
 Appendix A
References
 
Conference discussion

Dr P. Goldstraw (London, U.K.): Given that your overall median survival is 2 years, the same as patients having no surgery at all, only chemoradiotherapy, given that your results are entirely in keeping with the results of the intergroup study and the EORTC study, why do you say a randomized prospective study is necessary? What grounds for such optimism do you have?

Dr M. Pruyt (Avignon, France): We just had a little group of 107 patients and it was a fact a retrospective study.

Dr Goldstraw: Well a little group of 107 patients is a big group. What encouragement do you get from the results of your 107 patients that lead you to think that you need 400 or 500 patients in a randomized prospective study?

Dr Pruyt: Because there is a big response of this range of tumor necrosis and we saw in the slides that the tumor necrosis is highly significant for the overall survival.

Dr Goldstraw: But your tumor necrosis rate, the complete pathological response rate, is inflated by including patient with microscopic residual disease, which is not complete pathological response.

Dr Pruyt: That is correct.

Dr J. Kuzdzal (Zakopane, Poland): Your results of patients with N0–N1 disease after induction therapy were no different than with N2 disease. Do you propose any restaging after chemoradiation? Is it necessary to restage these patients or is it not? There is an ongoing discussion whether to restage these patients. Your results show something else, that it is not necessary.

Dr Pruyt: Yes indeed.


   Acknowledgments
 
Thanks go to Drs Alain Rabanit, Aline Soutif, Sandrine Hirschi, Robert Herve and Gilbert Chauvin who treated the patients; Pr. Elisabeth Quoix for her help in revising the manuscript; Marie-Claire Tasso who managed the data.


   Footnotes
 
{star} Presented at the 15th European Conference on General Thoracic Surgery, Leuven, Belgium, June 3–6, 2007.


   References
Top
 Abstract
 1. Introduction
 2. Patients and methods
 3. Results
 4. Discussion
 5. Conclusion
 Appendix A
 References
 

  1. Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 1992;53(6):992-998.[Abstract]
  2. Rosell R, Abad-Esteve A, Moreno I, Barnadas A, Carles J, Fernandez C, Ribelles N, Culubret M. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer. Cancer 1990;65(8):1692-1699.[CrossRef][Medline]
  3. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam Jr. JB, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M, Atkinson EN, Hong WK. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 1994;86(9):673-680.[Abstract/Free Full Text]
  4. Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, Braun D, Breton JL, Lemarie E, Gouva S, Paillot N, Brechot JM, Janicot H, Lebas FX, Terrioux P, Clavier J, Foucher P, Monchatre M, Coetmeur D, Level MC, Leclerc P, Blanchon F, Rodier JM, Thiberville L, Villeneuve A, Westeel V, Chastang C. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small cell lung cancer. J Clin Oncol 2002;20(1):247-253.[Abstract/Free Full Text]
  5. Betticher DC, Hsu Schmitz SF, Totsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003;21(9):1752-1759.[Abstract/Free Full Text]
  6. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi III AT, Weick JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR, Fosmire H, Taylor SA, Stelzer KJ, Beasley KR, Livingston RB. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13(8):1880-1892.[Abstract/Free Full Text]
  7. Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D. Induction chemoradiation and surgical resection for superior sulcus non-small cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 2007;25(3):313-318.[Abstract/Free Full Text]
  8. Albain KS, Swann RS, Rusch VW, Turrisi III AT, Shepherd F, Smith CJ, Gandara D, Johnson DH, Green MR, Miller RC, Intergroup NALC Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). Proc Am Soc Clin Oncol 2005;23:624s(Abstr. 7014).
  9. Turrisi III AT, Scott CB, Rusch VW, Albain KS, Shepherd F, Smith CJ, Chen Y, Livingston R, Gandara D, Darling G, Johnson DH, Green MR. Randomized trial of chemoradiotherapy to 61 Gy [no S] versus chemoradiotherapy to 45 Gy followed by surgery [S] using cisplatin etoposide in stage IIIa non-small cell lung Cancer (NSCLC): intergroup trial 0139, RTOG (9309). Proc Am Soc Ther Rad Oncol 2003;57(2 Supplement):S125-S126(Abstr. 4).
  10. Choi NC, Carey RW, Daly W, Mathisen D, Wain J, Wright C, Lynch T, Grossbard M, Grillo H. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small cell lung cancer. J Clin Oncol 1997;15(2):712-722.[Abstract/Free Full Text]
  11. Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H, Krause B, Mueller MR, Stahl M, Flasshove M, Budach V, Greschuchna D, Konietzko N, Sack H, Seeber S. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998;16(2):622-634.[Abstract]
  12. Galetta D, Cesario A, Margaritora S, Porziella V, Piraino A, D’Angelillo RM, Gambacorta MA, Ramella S, Trodella L, Valente S, Corbo GM, Macis G, Mule A, Cardaci V, Sterzi S, Granone P, Russo P. Multimodality treatment of unresectable stage III non-small cell lung cancer: interim analysis of a phase II trial with preoperative gemcitabine and concurrent radiotherapy. J Thorac Cardiovasc Surg 2006;131(2):314-321.[Abstract/Free Full Text]
  13. Kwong KF, Edelman MJ, Suntharalingam M, Cooper LB, Gamliel Z, Burrows W, Hausner P, Doyle LA, Krasna MJ. High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. J Thorac Cardiovasc Surg 2005;129(6):1250-1257.[Abstract/Free Full Text]
  14. Park BB, Park JO, Kim H, Ahn YC, Choi YS, Kim K, Kim J, Shim YM, Ahn JS, Park K. Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer?. Lung Cancer 2006;53(3):323-330.[CrossRef][Medline]
  15. Fournel P, Robinet G, Thomas P, Souquet PJ, Lena H, Vergnenegre A, Delhoume JY, Le Treut J, Silvani JA, Dansin E, Bozonnat MC, Daures JP, Mornex F, Perol M. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005;23(25):5910-5917.[Abstract/Free Full Text]
  16. Gandara DR, Chansky K, Albain KS, Gaspar LE, Lara Jr. PN, Kelly K, Crowley J, Livingston R. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer 2006;8(2):116-121.[Medline]
  17. Reboul F, Brewer Y, Vincent P, Chauvet B, Faure CF, Taulelle M. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III non-small cell lung cancer: a phase II study. Int J Radiat Oncol Biol Phys 1996;35(2):343-350.[Medline]
  18. Vokes EE, Herndon II JE, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002;20(20):4191-4198.[Abstract/Free Full Text]
  19. Doddoli C, Barlesi F, Trousse D, Robitail S, Yena S, Astoul P, Giudicelli R, Fuentes P, Thomas P. One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: an uncertain balance between risks and benefits. J Thorac Cardiovasc Surg 2005;130(2):416-425.[Abstract/Free Full Text]
  20. Mansour Z, Kochetkova EA, Ducrocq X, Vasilescu, MD, Maxant G, Buggenhout A, Wihlm JM, Massard G. Induction chemotherapy does not increase the operative risk of pneumonectomy!. Eur J Cardiothorac Surg 2007;31(2):181-185.[Abstract/Free Full Text]
  21. Schmuecking M, Schneider CP, Presselt N, Baum RP, Leonhardi J, Hoeffken K, Niesen A, Mueller KM, Wendt TG, Bonnet R, Group L-MS Are timing of chemoradiation and early therapy response as detected by PET prognostic factors of a multimodality treatment approach for NSCLC stage III? (LUCAS-MD). Proc Am Clin Oncol 2007;25(18s)(Abstr. 7532).



This article has been cited by other articles:


Home page
 Eur. J. Cardiothorac. Surg.Home page
M. Tamura, M. A. Hoda, and W. Klepetko
Current treatment paradigms of superior sulcus tumours
Eur. J. Cardiothorac. Surg., October 1, 2009; 36(4): 747 - 753.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. J. Krasna
COUNTERPOINT: Pneumonectomy after chemoradiation: the risks of trimodality therapy.
J. Thorac. Cardiovasc. Surg., August 1, 2009; 138(2): 295 - 299.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
V. Steger, T. Walles, B. Kosan, T. Walker, T. Kyriss, S. Veit, J. Dippon, and G. Friedel
Trimodal Therapy for Histologically Proven N2/3 Non-Small Cell Lung Cancer: Mid-Term Results and Indicators for Survival.
Ann. Thorac. Surg., June 1, 2009; 87(6): 1676 - 1683.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Nicola Santelmo
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pourel, N.
Right arrow Articles by Reboul, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pourel, N.
Right arrow Articles by Reboul, F.
Related Collections
Right arrow Lung - cancer

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS